Clinical Trial Update: Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan [Phase 4]

View source ↗

Summary

Phase 4 trial updating exercise-induced pulmonary hypertension in systemic sclerosis and treatment with ambrisentan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension
• Shortness of Breath
• Systemic Sclerosis

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Systemic Sclerosis, Shortness of Breath | Phase 4 | Status: COMPLETED | Results posted: 2020-11-02